Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albendazole Dose and Interval for Lymphatic Filariasis
NCT00375583Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2006
- Primary completion
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of albendazole in lymphatic filariasis (LF), sponsored by National Institute of Allergy and Infectious Diseases. Started Sep 2006; status: completed.
02
Drugs
albendazole
03
Conditions
lymphatic filariasis (LF)
Beyond the preview
Go deeper on NCT00375583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00375583.